2. Search Result
Search Result
Results for "

ACHN

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

4

Natural
Products

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-19936A
    ACHN-975 TFA
    1 Publications Verification

    		 Bacterial Infection
    ACHN-975 TFA is a selective LpxC inhibitor and exhibits a subnanomolar LpxC inhibitory activity. ACHN-975 TFA is against a wide range of gram-negative bacterias with low MIC values (≤1 μg/mL) .
    ACHN-975 TFA
  • HY-16955A
    Plazomicin sulfate
    1 Publications Verification

    ACHN 490 sulfate

    		 Antibiotic Bacterial Infection Inflammation/Immunology
    Plazomicin (ACHN 490) sulfate is a potent aminoglycoside antibiotic in the fight against antimicrobial resistance. Plazomicin sulfate is against several multi-drug-resistant organisms, including carbapenem-resistant Enterobacteriaceae. Plazomicin sulfate has the potential to be used for multi-drug-resistant complicated urinary tract infections (cUTIs) or in combination for serious carbapenem-resistant Enterobacteriaceae infections .
    Plazomicin sulfate
  • HY-15004
    AUZ 454
    5 Publications Verification

    K03861

    		 CDK Cancer
    AUZ 454 (K03861) is a type II CDK2 inhibitor with Kd of 8.2 nM. AUZ 454 (K03861) inhibits CDK2 activity by competing with binding of activating cyclins.
    AUZ 454
  • HY-162520
    DJ-1-IN-1

    		Wnt Cancer
    DJ-1-IN-1 (compound 797780-71-3) is a DJ-1 inhibitor. DJ-1-IN-1 exhibits antiproliferative activity in ACHN cells with an IC50 value of 12.18 μM and can inhibit the Wnt signaling pathway. DJ-1-IN-1 can be used in cancer research .
    DJ-1-IN-1
  • HY-19936
    ACHN-975

    		Bacterial Infection
    ACHN-975 is a selective LpxC inhibitor and exhibits a subnanomolar LpxC inhibitory activity. ACHN-975 is against a wide range of gram-negative bacterias with low MIC values (≤1 μg/mL) .
    ACHN-975
  • HY-16955
    Plazomicin

    ACHN 490

    		 Antibiotic Bacterial Infection Inflammation/Immunology
    Plazomicin (ACHN 490) is a potent aminoglycoside antibiotic in the fight against antimicrobial resistance. Plazomicin has in vitro activity against several multi-drug-resistant organisms, including carbapenem-resistant Enterobacteriaceae. Plazomicin has the potential to be used for multi-drug-resistant complicated urinary tract infections (cUTIs) or in combination for serious carbapenem-resistant Enterobacteriaceae infections .
    Plazomicin
  • HY-121532
    (-)-Rasfonin

    		Ras Apoptosis Autophagy Cancer
    (-)-Rasfonin is a fungal secondary metabolite and inhibits small G proteins Ras. (-)-Rasfonin induces apoptosis, necrosis and autophagy in ACHN cells (a renal carcinoma cell line) .
    (-)-Rasfonin
  • HY-RS07530
    LARP6 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    LARP6 Human Pre-designed siRNA Set A contains three designed siRNAs for LARP6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    LARP6 Human Pre-designed siRNA Set A
    LARP6 Human Pre-designed siRNA Set A
  • HY-133541
    Glucopiericidin A

    		GLUT ADC Payload Apoptosis Cancer
    Glucopiericidin A is a natural piericidin compound obtained from a marine-derived Streptomyces strain. Glucopiericidin A serves as a glucose transporter (GLUT) chemical probe and suppresses glycolysis. Glucopiericidin A inhibits ATP-dependent filopodia protrusion with Piericidin A (PA; HY-114936) and has no effect alone. Glucopiericidin A induces cell apoptosis through reducing the reactive oxygen species (ROS) level by increasing PRDX1 and exhibits potent antitumor efficacy in ACHN mice xenografts .
    Glucopiericidin A
  • HY-N5093
    Glucodigifucoside

    		Others Cancer
    Glucodigifucoside, a cardenolide glycoside that could be isolated from the seeds of Digitalis purpurea, exhibits potent cytotoxicity against human renal adenocarcinoma cell line ACHN .
    Glucodigifucoside
  • HY-112055
    DIM-C-pPhOH
    Maximum Cited Publications
    7 Publications Verification

    		 Nuclear Hormone Receptor 4A/NR4A Apoptosis Cancer
    DIM-C-pPhOH is a nuclear receptor 4A1 (NR4A1) antagonist. DIM-C-pPhOH inhibits cancer cell growth and mTOR signaling, induce apoptosis and cellular stress. DIM-C-pPhOH reduces cell proliferation with IC50 values of 13.6 μM and 13.0 μM for ACHN cells and 786-O cells, respectively .
    DIM-C-pPhOH
  • HY-N14056
    Chrolactomycin

    		Bacterial Infection Cancer
    Chrolactomycin is found in the strain of Streptomyces sp. 569N-3. The IC50 of Chrolactomycin for ACHN, A431, McF-7 and T24 cells are 1.2 μM, 1.6 μM, 0.69 μM and 0.45 μM, respectively. Chrolactomycin has only anti-Gram-positive bacteria activity with the MIC of 5.2-10.4 μg/mL .
    Chrolactomycin
  • HY-170604
    MMP-2 Inhibitor-4

    		MMP Cardiovascular Disease Cancer
    MMP-2 Inhibitor-4 (Compound 5g) is an MMP-2 inhibitor with an IC50 of 152.62 nM. MMP-2 Inhibitor-4 can reduce the levels of MMP-2 in the K562 cell line through stable binding at the MMP-2 active site, and it demonstrates strong antiangiogenic effects in the ACHN cell line. MMP-2 Inhibitor-4 holds promise for research in chronic myeloid leukemia (CML) .
    MMP-2 Inhibitor-4
  • HY-110021
    Fenoldopam hydrochloride

    SKF 82526 hydrochloride

    		 Dopamine Receptor Histone Demethylase Apoptosis Cardiovascular Disease Cancer
    Fenoldopam (SKF 82526) hydrochloride is a D1 receptor agonist and a novel lysine-specific demethylase 1 (LSD1) inhibitor (IC50=0.8974 μM). Fenoldopam hydrochloride shows anti-hypertensive effects, anti-cancer cell proliferation activity and can induce cells apoptosis .
    Fenoldopam hydrochloride
  • HY-112056
    DIM-C-pPhCO2Me
    1 Publications Verification

    		 Nuclear Hormone Receptor 4A/NR4A Apoptosis DAPK Isocitrate Dehydrogenase (IDH) PERK Cancer
    DIM-C-pPhCO2Me is a nuclear receptor 4A1 (NR4A1) antagonist. DIM-C-pPhCO2Me induces Apoptosis. DIM-C-pPhCO2Me decreases PAX3-FOXO1A, N-Myc, Rassf4, MyoD1, Grem1, and DAPK1 proteins. DIM-C-pPhCO2Me decreases expression of TXNDC5 and IDH1, induces markers of ER stress (CHOP, ATF4 and p-PERK). DIM-C-pPhCO2Me inhibits renal cell carcinoma, breast cancer. DIM-C-pPhCO2Me can also be used in rhabdomyosarcoma research .
    DIM-C-pPhCO2Me
  • HY-161385
    Topoisomerase I inhibitor 16

    		Topoisomerase Cancer
    Topoisomerase I inhibitor 21 (Compound 3e) is an inhibitor for Topoisomerase I through stabilization of enzyme-DNA complex. Topoisomerase I inhibitor 21 exhibits antiproliferative activity in 39 human cancer cells (JFCR39) with mean GI50 39 nM .
    Topoisomerase I inhibitor 16
  • HY-B0735A
    Fenoldopam mesylate
    4 Publications Verification

    Fenoldopam methanesulfonate; SKF-82526 mesylate

    		 Dopamine Receptor Apoptosis Cardiovascular Disease Cancer
    Fenoldopam mesylate (SKF-82526) is a D1 receptor agonist and a novel lysine-specific demethylase 1 (LSD1) inhibitor (IC50=0.8974 μM). Fenoldopam mesylate shows anti-hypertensive effects, anti-cancer cell proliferation activity and can induce cells apoptosis .
    Fenoldopam mesylate
  • HY-B0735AR
    Fenoldopam mesylate (Standard)

    Fenoldopam methanesulfonate (Standard); SKF-82526 mesylate (Standard)

    		 Reference Standards Dopamine Receptor Apoptosis Cardiovascular Disease Cancer
    Fenoldopam (mesylate) (Standard) is the analytical standard of Fenoldopam (mesylate). This product is intended for research and analytical applications. Fenoldopam mesylate (SKF-82526) is a D1 receptor agonist and a novel lysine-specific demethylase 1 (LSD1) inhibitor (IC50=0.8974 μM). Fenoldopam mesylate shows anti-hypertensive effects, anti-cancer cell proliferation activity and can induce cells apoptosis .
    Fenoldopam mesylate (Standard)
  • HY-149388
    Anticancer agent 139

    		Microtubule/Tubulin Cancer
    Anticancer agent 139 (Compound 6h) has potent anticancer activity. Anticancer agent 139 displayed a π–cationic interaction with the residue Lys352 of Tublin. Anticancer agent 139 has good anticancer activity against SNB-19, OVCAR-8, and NCI-H40 with PGIs of 86.61, 85.26, and 75.99, respectively. Anticancer agent 139 also has moderate anticancer activity against HOP-62, SNB-75, ACHN, NCI/ADR-RES, 786-O, A549/ATCC, HCT-116, and MDA-MB-231 with PGIs of 67.55, 65.46, 59.09, 59.02, 57.88, 56.88, 56.53, 56.4, and 51.88 respectively .
    Anticancer agent 139

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: